(Q38188821)

30 August 2017

title

Achieving glycaemic targets with basal insulin in T2DM by individualizing treatment (English)

1 reference

30 August 2017

Vivian A Fonseca

1

1 reference

30 August 2017

Michelle A Haggar

series ordinal

2

1 reference

30 August 2017

publication date

18 February 2014

1 reference

Nature Reviews Endocrinology

30 August 2017

published in

1 reference

30 August 2017

volume

10

1 reference

30 August 2017

issue

5

1 reference

30 August 2017

page(s)

276-281

1 reference

Defining and characterizing the progression of type 2 diabetes

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Glucagon physiology and pathophysiology in the light of new advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Systematic review: glucose control and cardiovascular disease in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Hypoglycemia, diabetes, and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Standards of medical care in diabetes--2014

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Three-year efficacy of complex insulin regimens in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

The Treat-to-Target Trial and related studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Early insulin therapy for type 2 diabetic patients: more cost than benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Dispelling myths and removing barriers about insulin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Standards of medical care in diabetes--2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Reusable and disposable insulin pens for the treatment of diabetes: understanding the global differences in user preference and an evaluation of inpatient insulin pen use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

The importance of hypoglycemia in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Survey of insulin site rotation in youth with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

The use of insulin in elderly patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Diabetes medications related to an increased risk of falls and fall-related morbidity in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Frequency of hypoglycemia and its significance in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Insulin detemir versus insulin glargine for type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Type 2 diabetes in children and adolescents. American Diabetes Association

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Effect of Renal Disease on Renal Uptake and Excretion of Insulin in Man

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.17

Removing barriers to insulin use

31 March 2020

1 reference

12 December 2020

Emergence of type 2 diabetes mellitus in children: epidemiological evidence

1 reference

12 December 2020

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)

1 reference

12 December 2020

Update on the Canadian Diabetes Association 2008 clinical practice guidelines.

1 reference

12 December 2020

Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2014.17

1 reference

30 August 2017

1 reference